Acute myeloid leukemia
Conditions
Interventions
experimental group:Decitabine: 35 mg-75mg Subcutaneous injection one time/day, consecutively 7 days in a month x 8 -12 times
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
15 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients between the ages of 18-70 years, male and female are not limited; 2. Azacytidine was used as routine maintenance therapy for 1 month after transplantation; 3. Patients who have not received maintenance treatment after transplantation, and have turned positive MRD at any time; 4. Patients with normal blood routine should be satisfied with each condition; 5. Patients who are able to understand and willing to sign the informed consent for this trial.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with uncontrolled heart failure, unstable angina, arrhythmia or mental disease; serious heart, lung, liver and kidney diseases; 3. Patients with uncontrollable infectious diseases; 4. HIV infected patients; 5. Patients with stage 3 or above chronic kidney disease; 6. Hematology recurred completely.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission of hematology on morphology;Minimal residue diseases;event-free survival;overall survival;cumulative disease rate of relapse;relapse; | — |
Secondary
| Measure | Time frame |
|---|---|
| early mortality rate ; | — |
Countries
China
Contacts
Public ContactWang Li
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed